Evolus, Inc. (EOLS) stock
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.07+0.38 (+5.68%)
Close on Nov 18, 2026Market cap $466.98MP/E –Yield –
Evolus operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Evolus's operating income for the twelve months ending Jun 30, 2026 was -$18.67M. For fiscal 2025 it was -$32.66M. The highest annual figure on record is -$11.73M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$32.66M | – |
| FY2024 | Dec 31, 2024 | -$34.41M | – |
| FY2023 | Dec 31, 2023 | -$49.23M | – |
| FY2022 | Dec 31, 2022 | -$65.33M | – |
| FY2021 | Dec 31, 2021 | -$44.41M | – |
| FY2020 | Dec 31, 2020 | -$153.07M | – |
| FY2019 | Dec 31, 2019 | -$98.95M | – |
| FY2018 | Dec 31, 2018 | -$46.14M | – |
| FY2017 | Dec 31, 2017 | -$11.73M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.54M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.85M | – |
| Q4 FY2025 | Dec 31, 2025 | $4.22M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.50M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.17M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.47M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.70M | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.92M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.64M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.44M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.12M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.04M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.64M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.90M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.35M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.45M | -292.5% |
| Q4 FY2021 | Dec 31, 2021 | -$18.03M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.11M | – |
| Q2 FY2021 | Jun 30, 2021 | -$15.29M | – |
| Q1 FY2021 | Mar 31, 2021 | $8.03M | – |
| Q4 FY2020 | Dec 31, 2020 | -$108.03M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.76M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.89M | – |
| Q1 FY2020 | Mar 31, 2020 | -$17.40M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.54M | – |
| Q3 FY2019 | Sep 30, 2019 | -$25.14M | – |
| Q2 FY2019 | Jun 30, 2019 | -$36.00M | – |
| Q1 FY2019 | Mar 31, 2019 | -$25.27M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.51M | – |
| Q3 FY2018 | Sep 30, 2018 | -$11.49M | – |
| Q2 FY2018 | Jun 30, 2018 | -$16.10M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.05M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.86M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.62M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.28M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.98M | – |
See a number that looks wrong?